drugset / Trial / NCT05470998

L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

NCT05470998

Phase 3 Completed 50 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

Timeline

Start
2022-07-25
Primary completion
2024-10-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator L-arginine Small molecule 0.1 g/kg
Comparator L-arginine Small molecule 0.2 g/kg
Comparator L-arginine Small molecule 1000 mg

Indications